ESMO Congress 2019
Clinical benefits from antibody–drug conjugates are reported for bladder cancer
At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing
Potential advance in HER+ patients with combination therapy
Results from the monarcHER and KATE2 trials presented
Slow progress on female leadership in oncology
Updated results from the ESMO Women for Oncology study monitoring the representation of women at major national and international congresses and societies
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer